EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
暂无分享,去创建一个
F. Cappuzzo | M. Varella‐Garcia | D. Eberhard | J. Rüschoff | K. Geenen | J. Diebold | S. Arbogast | M. Kockx | F Cappuzzo | S Arbogast | J Diebold | M Varella-Garcia | D A Eberhard | K Geenen | A Hirschmann | M Kockx | I Nagelmeier | J Rüschoff | M Schmitt | A. Hirschmann | I. Nagelmeier | M. Schmitt | M. Varella-Garcia
[1] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[2] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[3] Zhong Wen-zhao,et al. Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .
[4] F. Cappuzzo,et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Digel,et al. Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[7] R. Ramlau,et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) , 2008 .
[8] Edward S. Kim,et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) , 2008 .
[9] L. Crinò,et al. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. , 2009, Lung cancer.
[10] John Mendelsohn,et al. Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.
[11] Steven E Schild,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[12] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[13] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[14] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[15] G. Giaccone,et al. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Adjei,et al. Small cell lung cancer. , 2008, Mayo Clinic proceedings.
[17] Lesley Seymour,et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Sequist,et al. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. , 2008, Annual review of medicine.
[19] F. Hirsch,et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[21] F Berrino,et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] I. Tannock,et al. Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Varella‐Garcia,et al. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay , 2006, Diagnostic pathology.
[24] Edward S. Kim,et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02 , 2007 .
[25] R. Herbst,et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] F. Shepherd,et al. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes , 2008, Current opinion in oncology.
[27] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[28] F. Hirsch,et al. Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.
[29] V. Kovač,et al. Erlotinib in previously treated non-small-cell lung cancer , 2006 .
[30] G. Scagliotti,et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[32] Edward S. Kim,et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.
[33] G. Kalemkerian,et al. Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.